Allogene Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.About ALLO
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
CEODavid D. Chang
CEODavid D. Chang
Employees229
Employees229
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2017
Founded2017
Employees229
Employees229
ALLO Key Statistics
Market cap334.85M
Market cap334.85M
Price-Earnings ratio-1.52
Price-Earnings ratio-1.52
Dividend yield—
Dividend yield—
Average volume3.07M
Average volume3.07M
High today$1.54
High today$1.54
Low today$1.46
Low today$1.46
Open price$1.48
Open price$1.48
Volume2.35M
Volume2.35M
52 Week high$3.78
52 Week high$3.78
52 Week low$0.8621
52 Week low$0.8621
Stock Snapshot
As of today, Allogene Therapeutics(ALLO) shares are valued at $1.49. The company's market cap stands at 334.85M, with a P/E ratio of -1.52.
As of 2026-01-08, Allogene Therapeutics(ALLO) stock has fluctuated between $1.46 and $1.54. The current price stands at $1.49, placing the stock +2.4% above today's low and -3.2% off the high.
The Allogene Therapeutics(ALLO)'s current trading volume is 2.35M, compared to an average daily volume of 3.07M.
In the last year, Allogene Therapeutics(ALLO) shares hit a 52-week high of $3.78 and a 52-week low of $0.86.
In the last year, Allogene Therapeutics(ALLO) shares hit a 52-week high of $3.78 and a 52-week low of $0.86.
Analyst ratings
80%
of 15 ratingsBuy
80%
Hold
13.3%
Sell
6.7%
People also own
Based on the portfolios of people who own ALLO. This list is generated using Robinhood data, and it’s not a recommendation.